Valerie Voon1, Marc N Potenza, Teri Thomsen. 1. Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, Maryland 20892-1428, USA. voonv@ninds.nih.gov
Abstract
PURPOSE OF REVIEW: A range of impulse control and repetitive behaviors presumed to be related to dopaminergic medications has been recognized in Parkinson's disease. These behaviors are linked by their incentive or reward-based and repetitive natures and overlap with addictions. The behaviors include pathological gambling, hypersexuality, compulsive shopping, and compulsive eating and are related to punding and compulsive medication use. In patients on dopamine agonists, these behaviors as a group are relatively common, can have potentially devastating psychosocial consequences and are commonly hidden. RECENT FINDINGS: Recent studies have investigated prevalence rates and associated factors. The literature on these behaviors in Parkinson's disease, including definitions, epidemiology, pathophysiology and management, is reviewed. The relationship to medications, Parkinson's disease and individual susceptibility is examined. SUMMARY: These behaviors can affect up to 14% of Parkinson's disease patients on dopamine agonists. Clinicians should warn patients prior to initiating dopamine agonists and enquire about these behaviors during follow up.
PURPOSE OF REVIEW: A range of impulse control and repetitive behaviors presumed to be related to dopaminergic medications has been recognized in Parkinson's disease. These behaviors are linked by their incentive or reward-based and repetitive natures and overlap with addictions. The behaviors include pathological gambling, hypersexuality, compulsive shopping, and compulsive eating and are related to punding and compulsive medication use. In patients on dopamine agonists, these behaviors as a group are relatively common, can have potentially devastating psychosocial consequences and are commonly hidden. RECENT FINDINGS: Recent studies have investigated prevalence rates and associated factors. The literature on these behaviors in Parkinson's disease, including definitions, epidemiology, pathophysiology and management, is reviewed. The relationship to medications, Parkinson's disease and individual susceptibility is examined. SUMMARY: These behaviors can affect up to 14% of Parkinson's diseasepatients on dopamine agonists. Clinicians should warn patients prior to initiating dopamine agonists and enquire about these behaviors during follow up.
Authors: R Carron; V Fraix; C Maineri; E Seigneuret; B Piallat; P Krack; P Pollak; A L Benabid; Stéphan Chabardès Journal: J Neural Transm (Vienna) Date: 2010-12-29 Impact factor: 3.575
Authors: Daniel O Claassen; Wery P M van den Wildenberg; K Richard Ridderinkhof; Charles K Jessup; Madaline B Harrison; G Frederick Wooten; Scott A Wylie Journal: Behav Neurosci Date: 2011-08 Impact factor: 1.912
Authors: Lynn Marie Trotti; Cathy A Goldstein; Christopher G Harrod; Brian B Koo; Denise Sharon; Rochelle Zak; Ronald D Chervin Journal: J Clin Sleep Med Date: 2015-03-15 Impact factor: 4.062
Authors: Brian E Roe; Michael R Tilley; Howard H Gu; David Q Beversdorf; Wolfgang Sadee; Timothy C Haab; Audrey C Papp Journal: PLoS One Date: 2009-08-20 Impact factor: 3.240